Trial Profile
A Phase I/II Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Feb 2022
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Cefixime; Irinotecan
- Indications Solid tumours
- Focus Adverse reactions
- 26 Oct 2020 Status changed from active, no longer recruiting to completed.
- 26 Feb 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Apr 2019.
- 26 Feb 2019 Status changed from recruiting to active, no longer recruiting.